129 results about "Polypill" patented technology

The invention belongs to the technical field of traditional Chinese medicine preparation, and particularly relates to a peach kernel and safflower four-ingredient decoction compound preparation and a preparation method and a quality control method thereof. The invention provides a preparation method of a peach kernel and safflower four-component decoction compound preparation by screening and optimizing an enrichment method of volatile oil in extraction, concentration, inclusion and drying processes on the basis of an ancient water decoction process. According to the peach kernel and safflower four-drug decoction compound preparation prepared by the invention, the quality consistency with a reference sample is realized, including the consistency of each content index in the compound preparation with the reference sample and the consistency of a fingerprint spectrum with the reference sample; especially, characteristic peaks of volatile components-ligustilide, senkyunolide I and senkyunolide A are presented in the fingerprint spectrum, and the consistency of the content of the volatile oil is determined. Moreover, the quality control method provided by the invention is expected to be used for quality control of industrial large-scale production of a classic famous prescription, namely the peach kernel and safflower four-ingredient decoction compound preparation, and has a good application prospect.

The method comprises the following steps: dissolving lipoic acid and a drug in an organic solvent to form a homogeneous solution, dropwise adding deionized water while stirring, then adding a reducing agent, initiating lipoic acid polymerization and drug co-assembly in situ at 20-40 DEG C to form a drug-loaded micelle solution, and carrying out freeze drying on the drug-loaded micelle solution to obtain the nano-preparation drug based on polylipoic acid. And dialyzing and purifying to obtain the nano preparation medicine based on polylipoic acid. The preparation method is characterized in that lipoic acid has dual characteristics of a drug carrier matrix and a dynamic crosslinking monomer, carrier synthesis and efficient drug encapsulation are synchronously realized through one-step in-situ polymerization-co-assembly, and the technical bottleneck that a traditional nano-carrier needs pre-synthesis and step-by-step drug loading is broken through. The method has the following practicability: (1) the process is simple and efficient, complex equipment is not needed, and reaction conditions are mild; (2) the drug loading performance is excellent, and the particle size is uniform and adjustable (50-300 nanometers); (3) a polylipoic acid skeleton endows the nano-drug preparation with environmental responsiveness, and intelligent drug release can be realized; and (4) the method is suitable for hydrophobic drugs and compound preparations. The method provides a high-load, high-stability and stimuli-responsive nanocrystallization solution for hydrophobic drug delivery, and has application value in the field of nano-medicines.

The present invention relates to compounds, pharmaceutical compositions, combined preparations, and dosage regimens for treating, inhibiting the progression, and preventing cardiovascular calcification, and in particular, coronary calcification, aortic artery calcification, and aortic valve calcification comprising inositol phosphates. In a particular aspect the disclosure provides a dosage regimen for treating, inhibiting the progression, or preventing cardiovascular calcification comprising the administration of about 200 mg to about 700 mg of myo-inositol hexaphosphate per administration.

The invention provides a compound preparation containing curcumin nano-particles as well as a preparation method and application of the compound preparation. Curcumin is wrapped by alcohol-soluble protein to form nano-particles, and the nano-particles are used as a Pickering milk solid emulsifier for emulsifying and dispersing vitamin D and olive oil into an oil phase to form a stable droplet structure; furthermore, polysaccharide with enteric characteristics is used as a water-phase carrier material, and the emulsion is encapsulated in the pellet by using a hole sharpening-solidification method, so that the solidification of the liquid medicine (the emulsion) is realized; the three natural components, namely the curcumin, the vitamin D and the olive oil, are ingeniously integrated into a whole; the targeting property of the medicine at the colon part is improved; meanwhile, the destructive effect of the gastrointestinal tract environment on the medicine carrying nanoparticles is reduced.

The invention discloses an establishment method of an HPLC (high performance liquid chromatography) characteristic chromatogram of granules for treating common cold and clearing heat and a component content test thereof, and belongs to the technical field of pharmaceutical analys.According to the research, the HPLC characteristic chromatogram of the granules for treating common cold and clearing heat is established under the same chromatographic condition by adopting a high performance liquid chromatography, and the overall internal quality in a preparation is comprehensively reflected; the method for simultaneously determining the content of amygdalin, puerarin, cimicifugin and corydalis bungeana is established, methodology verifies that the method is simple, convenient and feasible, has good stability and repeatability, and can be used for detection in production process monitoring and quality evaluation of the cold and heat clearing granules to ensure that the quality of the cold and heat clearing granules meets the standard. The scheme not only scientifically restores the overall pharmacodynamic material basis of the compound preparation, but also provides a new generalizable normal form for quality control of traditional Chinese medicines with the advantages of low cost and high efficiency, and has milestone significance for promoting industry standardization and internationalization.

The invention discloses a quality control method of a Beijing medicine compound preparation, and particularly relates to the field of quality control methods. Comprising the steps of comprehensive detection of medicinal materials, multi-component content determination, biological activity evaluation, quality consistency evaluation and the like. The quality stability of the medicinal materials is guaranteed from the source by determining the medicinal material producing area, the harvesting time and the processing technology preset standard; a biological activity detection model related to efficacy is established, and the quality standard and the efficacy are tightly combined; a compound preparation quality database is constructed, principal component analysis and clustering analysis are used for regular review analysis, and quality control standards and methods are dynamically adjusted and optimized; and a quality early warning mechanism is formulated, and quality problems are handled in time. According to the method, the quality is comprehensively controlled from multiple dimensions, the quality stability of preparations in different batches is ensured, the disjunction of the quality and the efficacy is effectively avoided, and the safety and the effectiveness of the Beijing medicine compound preparation are ensured.

The invention belongs to the technical field of traditional Chinese medicines, and particularly discloses application of a dampness-removing and itching-relieving decoction composition based on S1P-S1PRs pathway regulation in treatment of psoriasis. According to the present invention, the dampness removing and itching relieving decoction composition is used for treating psoriasis, can provide the treatment effect through multiple ways and multiple targets, can significantly improve the skin lesion condition of psoriasis patients, and can reduce the PASI score; as a traditional Chinese medicine compound preparation, the dampness-removing and itching-relieving decoction composition is small in side effect, high in safety and suitable for long-term use.

This invention belongs to the field of quality testing technology for traditional Chinese medicine preparations. Specifically, it provides a method for constructing a fingerprint spectrum and a quality testing method for a Tiaogan Decoction compound preparation. The fingerprint spectrum construction method of the Tiaogan Decoction compound preparation described in this invention uses octadecylsilane-bonded silica gel as the packing material and acetonitrile-phosphoric acid aqueous solution as the mobile phase for gradient elution. The elution program was obtained through repeated experiments. Under the elution conditions of this invention, not only is the number of common peaks significantly increased (up to 22), but each common peak also has a good peak shape, good separation effect, and stable baseline. This allows for a more comprehensive, clear, and effective quality testing of the Tiaogan Decoction compound preparation.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

Combinations of oxylanthanum carbonate and tenapanor for reducing serum phosphate levels in patients with end-stage renal disease (ESRD) and / or chronic kidney disease (CKD).

Provided are pharmaceutical compositions comprising a combination therapy having therapeutically effective amounts of sodium 4-phenyIbutylate and tauroursodeoxycholic acid for the treatment of an ocular condition in a subject. Also provided herein are methods using the combination therapy, and a pharmaceutical composition thereof, for preventing or treating an ocular condition in a subject.

The invention belongs to the technical field of medicines, and particularly relates to tripterine-loaded nano-particles as well as a preparation method and application thereof, and the tripterine-loaded nano-particles (Cel-GDNPs) comprise ginger exosome (GDNPs) and tripterine (Cel) encapsulated in the ginger exosome. According to the invention, the Cel is used as a therapeutic drug, and the adopted carrier GDNPs has anti-inflammatory activity, so that when the Cel and the GDNPs are used for treating inflammatory diseases such as colitis and the like, the Cel and the GDNPs can play a multi-component synergistic therapeutic effect, and compared with the single use of the Cel or the GDNPs, the expression of proinflammatory factors (such as TNF-alpha, IL-1beta and IL-6) can be more effectively inhibited, so that the synergistic therapeutic effect is realized; a new strategy is provided for developing a novel natural compound preparation.

This invention discloses a compound preparation for treating vascular dementia and its preparation method. The active pharmaceutical ingredient consists of protopanaxadiol and gallic acid in a 1:1 mass ratio, and the dosage form is liposomes. The preparation method includes extraction, mixing, liposome preparation, and optional freeze-drying steps: protopanaxadiol and gallic acid are extracted and purified from ginseng rhizome and Terminalia chebula fruit, respectively. After mixing, they are combined with phospholipids and cholesterol to prepare a lipid membrane. The membrane is then homogenized by hydration, low-temperature ultrasound, and high-pressure microfluidic jet to obtain a homogeneous liposome suspension, which can be further freeze-dried into a freeze-dried powder. The 1:1 composition of protopanaxadiol and gallic acid targets multiple points on the pathological mechanism of vascular dementia, showing significant therapeutic effects and broad application prospects. This preparation uses a liposome dosage form to improve the bioavailability of the active ingredient, the preparation process parameters are controllable, the active ingredient has high purity, the liposomes have uniform particle size, high encapsulation efficiency, and good stability.

The invention discloses a method for characterizing volatile components in a compound pseudo-ginseng and salvia miltiorrhiza capsule based on gas chromatography-mass spectrometry, and relates to the technical field of compound pseudo-ginseng and salvia miltiorrhiza capsule detection, and the method comprises the following steps: (1) preparing a compound pseudo-ginseng and salvia miltiorrhiza capsule test solution; and (2) detecting the volatile components in the traditional Chinese medicine compound test solution by adopting a triple quadrupole gas chromatograph-mass spectrometer. According to the method, volatile oil of a trace component of rhizoma cyperi in a compound preparation is fully retained and extracted by pre-treating the compound pseudo-ginseng and salvia miltiorrhiza capsule, and after detection by the method, a quasi-molecular ion peak can be obtained, and a fragment ion peak containing rich structure information can be obtained, so that the structure information of the compound can be quickly and accurately obtained.

The invention discloses an anti-hepatic fibrosis traditional Chinese medicine compound preparation and application thereof.The anti-hepatic fibrosis traditional Chinese medicine compound preparation is prepared from herba artemisiae scopariae, parched fructus gardeniae, roasted rhizoma atractylodis macrocephalae, turtle shells, radix bupleuri, rhizoma corydalis, herba desmodii styracifolii and herba scutellariae barbatae, all the medicines are compatible and have a synergistic effect, and the effects of clearing heat and promoting diuresis, promoting blood circulation to remove blood stasis, softening hardness to dissipate stagnation and tonifying spleen and qi are achieved together; the liver fibrosis is intervened from a plurality of target spots. Heat clearing and diuresis promoting can eliminate damp-heat evil damaging the liver; blood circulation of the liver can be improved by promoting blood circulation to remove blood stasis, and blood stasis is eliminated; the liver fibrosis hyperplasia can be resisted by softening hardness to dissipate stagnation, and the liver tissue hardening trend can be reversed; spleen invigorating and qi replenishing can enhance healthy qi of the body and improve the self-repairing ability of the liver. The multi-target and all-around treatment mode not only conforms to the holism concept of traditional Chinese medicine, but also conforms to the understanding of modern medicine on multi-factor and multi-link pathogenesis of hepatic fibrosis.

The invention belongs to the technical field of veterinary traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition for preventing and treating pregnancy toxemia and a compound preparation. The traditional Chinese medicine composition for preventing and treating pregnancy toxemia comprises the following raw materials in parts by weight: codonopsis pilosula, astragalus membranaceus, angelica sinensis, radix rehmanniae preparata, ligusticum wallichii and liquorice. The traditional Chinese medicine composition for preventing and treating the pregnancy toxemia can effectively treat the pregnancy toxemia, and after being combined with propylene glycol for use, the traditional Chinese medicine composition has the advantages that raw materials are easy to obtain, the preparation process is simple, administration is simple and easy to operate, toxic and side effects are low, veterinary drug residues are few, the effect taking speed is high, and the effect is good. The invention provides an effective way for preventing and treating the pregnancy toxemia.

Relates to a compound preparation and application thereof. The compound preparation comprises an anti-VEGF antibody or antigen binding fragment and an integrin GPIIb / IIIa antagonist. According to the compound preparation, the anti-VEGF antibody or antigen binding fragment and the integrin GPIIb / IIIa antagonist in the compound can be kept stable and have good binding activity, and the clinical use safety and effectiveness are improved.

The present disclosure relates to a drug combination and a method for the prevention and / or the treatment of a liver disease, the combination comprising lanifibranor or a deuterated form thereof and a GLP-1 / GIP / glucagon triple receptor agonist.

The invention discloses a novel compound preparation for resisting mycobacterium tuberculosis and a preparation method thereof.The compound preparation comprises glutathione active part and pyrazinamide, the weight ratio of glutathione to pyrazinamide is (2-4): 5, the glutathione active part comprises glutathione, an isolation stabilizer, a plasticizer, an anti-sticking agent and a first stabilizer, and the first stabilizer comprises glutathione, an isolation stabilizer, a plasticizer, an anti-sticking agent and a second stabilizer. According to the glutathione active part, firstly, a fluidized powder coating technology is adopted, and the relatively unstable active ingredient glutathione is subjected to powder coating; and preparing the coated components, pyrazinamide, a filler, a second stabilizer, an adhesive, a disintegrating agent and a lubricant into a specific preparation. According to the preparation, the hepatotoxicity during pyrazinamide medication is reduced, the compliance is increased, and meanwhile, the technical problem that a pyrazinamide glutathione preparation is unstable is solved.

The present application relates to a kind of cytidine choline dextrohydrotalcid derivatives and its preparation method and application, belong to biological medicine technical field.The present application is aimed at solving the technical problems of low blood-brain barrier penetration rate and limited treatment effect of existing edaravone dextrohydrotalcid compound preparation.The present application prepares a dextrohydrotalcid derivative (C-B) with boronic acid structure, then it is compounded with cytidine choline in specific pH buffer system, and forms cytidine choline dextrohydrotalcid derivative (C-D-B).The present application can effectively improve the efficiency of drug crossing blood-brain barrier by using the dynamic covalent characteristics of boronic ester bond and free radical responsiveness.The experimental results show that, compared with existing combination drug, the derivative of the present application can significantly reduce the infarction area of cerebral ischemia model animal, reduce cell damage and active oxygen level, and promote vascular regeneration, and show better treatment effect on ischemic brain injury.

The invention discloses an olmesartan medoxomil pharmaceutical co-crystal as well as a preparation, a preparation method and application thereof. The co-crystal is formed by olmesartan medoxomil and a specific co-crystal forming agent through intermolecular force. The invention also particularly provides a compound preparation containing the olmesartan medoxomil pharmaceutical co-crystal and hydrochlorothiazide. Through the eutectic technology, the invention fundamentally overcomes the inherent defects of low solubility and slow dissolution of olmesartan medoxomil as a BCS II drug. Experiments show that the preparation disclosed by the invention can realize rapid and complete drug release in vitro (the dissolution rate within 30 minutes is greater than or equal to 98%), the relative bioavailability of olmesartan in vivo can be improved by at least 180% compared with that of a reference preparation, and meanwhile, the eutectic structure ensures that the preparation has excellent chemical stability under an accelerated test condition. The invention provides an innovative solution for the development of an efficient and stable olmesartan medoxomil preparation.

The present invention provides a composition of nebivolol and amlodipine, comprising nebivolol, amlodipine and a pharmaceutical excipient. The nebivolol comprises one or more of nebivolol, a pharmaceutically acceptable salt thereof, and a solvate thereof. The amlodipine comprises one or more of amlodipine, a pharmaceutically acceptable salt thereof, and a solvate thereof. The pharmaceutical excipient is selected from one or more of a filler, a binder, a disintegrant, a lubricant, and a glidant. The composition does not contain a colorant and a film coating. The compound preparation of the present invention has good stability, and is beneficial to improving the antihypertensive efficacy, enhancing safety and tolerability, and reducing side effects. Compared to monotherapy, the present invention reduces the number of administered medications and improves the compliance of patients, is beneficial to improving the medication compliance of the elderly patients and individuals with dysphagia, maintains a stable plasma drug concentration, maintains long-term stable blood pressure in hypertensive patients, prevents the patients from discontinuing medication arbitrarily, and prevents disease recurrence and the progression of severe complications.

The present invention relates to the field of thin layer identification of Chinese medicinal materials in traditional Chinese medicine preparations, and in particular to a method for thin layer identification of Chinese herbal medicines and Chinese herbal medicines. It comprises the following steps: 1) crushing Chinese herbal medicines, soaking them in ethanol, ultrasonic extraction, collecting the filtrate, concentrating it, extracting it with petroleum ether, and evaporating it to obtain a residue; 2) dissolving the residue with petroleum ether and eluting it on a silica gel column three times, eluting it with petroleum ether for the first time, eluting it with petroleum ether-ethyl acetate with a volume ratio of 5 to 15:1 for the second time, and eluting it with petroleum ether-ethyl acetate with a volume ratio of 1 to 5:1 for the third time, collecting the third eluate, evaporating it to obtain a test sample; 3) spotting the test sample and the control medicinal material on a silica gel G thin layer plate, and performing thin layer chromatography identification with n-hexane-ethyl acetate as a developing agent. Chinese herbal medicines are compound preparations, and there is mutual influence between the components. The test solution prepared by the present invention can effectively purify the sample, reduce the interference of other components, and improve the accuracy of detection. At the same time, in the thin layer identification chromatogram, the developing agent is optimized, the color spots are clear, and it has strong specificity. The invention is used for quality control of Zhonghua Dieda Pills, ensuring the quality of the medicine and the safety, effectiveness and reliability of clinical medication.

The invention discloses a tranexamic acid-tyrosinase inhibitor hybrid conjugate as well as a preparation method and application thereof, belongs to the technical field of cosmetics and biological medicines, and particularly relates to a tranexamic acid-tyrosinase inhibitor hybrid conjugate shown in a formula (I) and a skin composition taking the compound as an active component. According to the hybrid conjugate, tranexamic acid and a tyrosinase inhibitor are integrated into a single-structure molecule through an ester bond, so that the transdermal efficiency can be improved and the transdermal dynamic difference limitation of a traditional compound preparation can be broken through by adjusting the hydrophilic-hydrophobic balance of the compound; and plasmin activity can be inhibited through cooperation of tranexamic acid, so that melanin generation signal transmission capability and tyrosinase inhibition capability of tyrosinase inhibitor specificity are reduced, and efficient and mild multi-channel whitening and spot fading are realized. As a whitening active matter, the tranexamic acid-tyrosinase inhibitor hybrid conjugate disclosed by the invention has a great application prospect in the aspects of whitening and freckle removing effects.

The invention relates to the technical field of traditional Chinese medicine quality control, and particularly discloses a traditional Chinese medicine compound preparation component identification method which comprises the following steps: taking a traditional Chinese medicine compound preparation, grinding and uniformly mixing to obtain powder; adding the powder into an extraction solvent, performing ultrasonic extraction and centrifugation, and taking supernate; component analysis is carried out on the supernate by adopting chromatography and mass spectrometry detection, and the chromatographic conditions are as follows: the chromatographic column is Thermo Hypersil gold C18 (1.9 [mu] m, 2.1 mm * 100 mm); the flow velocity is 0.3 mL / min, and the sample size is 10 [mu] L; mobile phases are as follows: a phase A is a 0.1% formic acid aqueous solution, a phase B is a 0.1% formic acid acetonitrile solution, and gradient elution is 0-1 min, 90% of A; in 1-15 min, 90%-10% of A is obtained; 15-17 min, 10% of A is taken; in 17-17.1 min, 10% to 90% of A is obtained; according to the component identification method of the traditional Chinese medicine compound preparation, qualitative analysis is conducted on the traditional Chinese medicine compound preparation through an LC-MS method, a basis and support are provided for quality control of the traditional Chinese medicine compound preparation, and a good foundation is provided for network pharmacology research.

Composition, in particular pharmaceutical composition, in the form of a fixed dosage (solid dosage form) for sucking and / or chewing, preferably for sucking, in particular lozenge, preferably for use in the prophylactic and / or therapeutic topical (local) treatment of inflammatory diseases of the mouth and throat, wherein the composition contains an effective, in particular pharmaceutically and / or therapeutically effective, amount of an active ingredient preferably suitable and / or effective for the topical (local) treatment of inflammatory diseases of the mouth and throat, in particular with antiseptic and / or antimicrobial properties, preferably with antibacterial and / or antiviral and / or antifungal properties, wherein the active ingredient is incorporated and / or embedded in a solid matrix, wherein the composition, in particular the solid dosage form and / or the matrix, releases the active ingredient upon topical (local) application and / or use, preferably by sucking and / or chewing, preferably by sucking, in the oral and pharyngeal cavity; wherein the active ingredient is octenidine, in particular in the form of a pharmaceutically compatible and / or physiologically acceptable salt or ester, preferably in the form of a pharmaceutically compatible and / or physiologically acceptable salt, particularly preferably octenidine dihydrochloride; and wherein the composition, in particular the solid dosage form and / or the matrix, furthermore and / or additionally contains at least one further ingredient (a) and / or (b), in particular (a) and (b), wherein the at least one further ingredient (a) and / or (b) is selected from the group of (a) Flavor modulators, in particular selected from the group of the following components (i), (ii) and / or (iii): (i) Bitter (taste) masking agents, in particular selected from the group consisting of bitter taste receptor antagonists, preferably 4-(2,2,3-trimethylcyclopentyl)butanoic acid, and saponins, preferably glycyrrhizic acid (glycyrrhizin) and its salts or esters and / or glycyrrhetinic acid (glycyrrhetin) and its salts or esters, complexing agents, in particular cyclodextrins, and combinations or mixtures thereof, (ii) Bitter substances, in particular coffee extract and / or tea extract and / or their respective bitter substances, preferably coffee extract and / or its bitter substances, (iii) preferably natural or nature-identical (aroma) oils and / or essential oils, in particular with antiseptic and / or antimicrobial properties, preferably with antibacterial, antifungal and / or antiviral properties, in particular selected from the group of anise oils, in particular star anise oil, peppermint oil, eucalyptus oil, lavender oil, tea tree oil, chamomile oil, clove oil, rosemary oil, caraway oil, cinnamon oil, sage oil and fennel oil, as well as combinations or mixtures thereof; in particular wherein the ingredient (a) and / or the flavor modulator comprises a combination of at least two different components (i), (ii) and / or (iii), preferably a combination of components (i), (ii) and (iii); (b) Acidulants, in particular saliva-stimulating and / or flavor-enhancing acidulants, preferably acidulants authorized under pharmaceutical and / or food law and / or acidulants authorized as pharmaceutical additives and / or food additives, in particular selected from the group of tartaric acid and its salts, in particular sodium tartrate, sodium potassium tartrate (Rochelle salt) and calcium tartrate, citric acid and its salts, metatartaric acid, fumaric acid, ascorbic acid, phosphoric acid and its salts, stannous chloride, in particular tin(II) chloride, malic acid, lactic acid, adipic acid, succinic acid and other pharmaceutically compatible and / or physiologically acceptable organic acids and their salts, as well as their combinations or mixtures.

The invention provides a compound preparation containing macarovir, a preparation method and application of the compound preparation in anti-influenza treatment, the multi-layer pellet compound preparation sequentially comprises a pellet core layer containing macarovir, an isolating layer, an active layer and an enteric layer from inside to outside, the pellet core layer containing macarovir and a sustained-release material, the isolating layer comprises an adhesive and an anti-sticking agent, the active layer comprises a hydrophobic layer and a hydrophobic layer, and the enteric layer comprises a hydrophobic layer and a hydrophobic layer. The active layer comprises oseltamivir phosphate and an adhesive, and the enteric-coated layer is made of synthetic polymer materials. The multi-layer pellet provided by the invention has good compressibility, disintegrability and lubricity. The compound preparation solves the problems of drug resistance, drug interaction and children medication compliance. The preparation is suitable for single-drug or combined treatment of influenza A / B viruses, and is especially suitable for children and drug-resistant influenza patients.

The invention relates to the technical field of menstruation regulating and beauty maintaining, and discloses a menstruation regulating and beauty maintaining paste formula and a preparation method thereof.The preparation method comprises the steps that S1, raw materials are prepared, specifically, the raw materials comprise main materials including reed-removed ginseng, American ginseng, cynanchum otophyllum, rubia yunnanensis, pearl powder, raw pseudo-ginseng, cooked pseudo-ginseng and the like; the formula of the cream for regulating menstruation and beautifying is a compound preparation cream formula which is formed according to the traditional Chinese medicine theory and clinical practice in combination with modern medicine science and technology knowledge, 63 traditional Chinese medicinal materials, three auxiliary materials and genuine Dongai water are used as medicines in the form of water, and the formula of the cream for regulating menstruation and beautifying is prepared on the basis of the traditional Chinese medicine theory and literature literature. A traditional preparation process and modern research results are combined, a cream preparation is prepared through careful decoction, the formula is clinically used, the effects of regulating menstruation and enriching blood, reinforcing qi and nourishing blood, expelling toxins and promoting qi circulation, tonifying kidney and spleen, promoting blood circulation to remove meridian obstruction, soothing liver and regulating qi, helping sleep and beautifying, removing freckles and beautifying and the like are positive, and no obvious toxic or side effect or adverse reaction exists.